-
EP4188952
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4188952
| EP4188952 - ANTI-CD22 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC CONSTRUCTS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 05.05.2023 Database last updated on 03.09.2024 | |
| Former | The international publication has been made Status updated on 04.02.2022 | Most recent event Tooltip | 28.06.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states National Research Council of Canada 1200 Montreal Road Ottawa, Ontario K1A 0R6 / CA | [2023/23] | Inventor(s) | 01 /
MCCOMB, Scott Ottawa, Ontario K1H 7A9 / CA | 02 /
WEERATNA, Risini Ottawa, Ontario K2G 6G5 / CA | 03 /
ARBABI-GHAHROUDI, Mehdi Ottawa, Ontario K4A 4P2 / CA | 04 /
NGUYEN, Tina Ottawa, Ontario K1G 6N6 / CA | 05 /
WU, Cunle Montreal, Québec H4B 1K9 / CA | [2023/23] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstraße 3 81675 München / DE | [2023/23] | Application number, filing date | 21850799.4 | 27.07.2021 | [2023/23] | WO2021CA51046 | Priority number, date | US202063058203P | 29.07.2020 Original published format: US 202063058203 P | [2023/23] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022020945 | Date: | 03.02.2022 | Language: | EN | [2022/05] | Type: | A1 Application with search report | No.: | EP4188952 | Date: | 07.06.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 03.02.2022 takes the place of the publication of the European patent application. | [2023/23] | Search report(s) | International search report - published on: | CA | 03.02.2022 | Classification | IPC: | C07K16/22, A61K35/17, A61K39/395, A61P35/00, A61P35/02, A61P37/06, C07K14/705, C07K16/46, C07K19/00, C12N15/13, C12N15/62, C12N15/867, C12N5/10, C12N7/01 | [2023/23] | CPC: |
C07K14/7051 (EP,IL,KR);
C07K16/2803 (EP,IL,KR,US);
A61K35/17 (KR);
A61K39/4611 (KR,US);
A61K39/4631 (KR,US);
A61K39/4633 (KR,US);
A61K39/464413 (KR,US);
A61K48/005 (EP,IL,KR);
A61P35/00 (EP,IL,KR,US);
A61P35/02 (EP,IL,KR);
A61P37/06 (EP,IL,KR);
C07K14/70517 (US);
C07K16/2809 (EP,IL,KR);
C12N5/0636 (KR);
A01K2227/105 (EP,IL);
A01K2267/0331 (EP,IL);
A61K2239/13 (KR,US);
C07K2317/22 (EP,IL,KR);
C07K2317/24 (US);
C07K2317/31 (EP,IL,KR,US);
C07K2317/35 (US);
C07K2317/565 (US);
C07K2317/569 (EP,IL,KR,US);
C07K2317/622 (EP,IL,KR);
C07K2317/64 (EP,IL,KR);
C07K2317/92 (EP,IL,KR,US);
C07K2319/03 (EP,IL,KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/23] | Title | German: | ANTI-CD22-EINZELDOMÄNENANTIKÖRPER UND THERAPEUTISCHE KONSTRUKTE | [2023/23] | English: | ANTI-CD22 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC CONSTRUCTS | [2023/23] | French: | ANTICORPS ANTI-CD22 À DOMAINE UNIQUE ET CONSTRUCTIONS THÉRAPEUTIQUES | [2023/23] | Entry into regional phase | 22.02.2023 | National basic fee paid | 22.02.2023 | Search fee paid | 22.02.2023 | Designation fee(s) paid | 22.02.2023 | Examination fee paid | Examination procedure | 22.02.2023 | Amendment by applicant (claims and/or description) | 22.02.2023 | Examination requested [2023/23] | Fees paid | Renewal fee | 27.06.2023 | Renewal fee patent year 03 | 27.06.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2019126464 (LENTIGEN TECH INC [US]); |